Thus, in about 15% of patients treatment with intracoronary streptokinase resulted in significant non-fatal bleeding from the femoral puncture site that required substantial transfusion support. Furthermore, there was a significant drop in haematocrit in patients without manifest bleeding. These results emphasise the need for more specific fibrinolytic agents.
Streptokinase is an effective thrombolytic agent in arterial and venous thrombotic disease.12 It can, however, produce massive, and potentially fatal bleeding due to systemic breakdown of fibrinogen and other clotting factors. Techniques of selective intra-arterial administration have been developed in an attempt to prevent such bleeding.
Intracoronary infusion of streptokinase in acute myocardial infarction has been shown to reduce in- farct Accepted for publication 12 July 1985 thrombolysis with low dose streptokinase was very effective in achieving reperfusion of occluded coronary arteries, systemic fibrinolysis was common. 69 The combination of intra-arterial instrumentation and systemic fibrinolysis when streptokinase is given by the intracoronary route may promote serious bleeding complications in acutely ill patients with myocardial infarction.
We analysed the risk of bleeding associated with intracoronary streptokinase treatment in acute myocardial infarction in a randomised multicentre study.
Patients and methods
The following four hospitals participated in a multicentre study in Patients in the control group underwent conventional treatment and had haemodynamic monitoring with a Swan-Ganz catheter in the same way as the patients in the streptokinase group. Anticoagulation with heparin and coumadin was identical to that given to patients in the streptokinase group. In 13 patients (9%) allocated to streptokinase treatment, catheterisation was not performed because of technical difficulties or because the patient refused. Three patients (2%) allocated to conventional treatment had intracoronary infusion of streptokinase during the acute phase. The results were analysed on the basis of intention to treat.
Venous blood samples were taken at admission and at 3, 6, 12, 18, 24, 36, and 48 hours after admission for laboratory tests including haemoglobin concentration and haematocrit. Standard medical care, including analgesics, diuretics, and inotropic support, was given to all patients.10 The occurrence of bleeding, thrombosis, pulmonary embolism, recurrent angina and infarction or both, left ventricular failure, and arrhythmias was recorded. Blood transfusions were given according to the instructions of the consulting physicians. Haemoglobin concentrations which were below 7-0 mmol/l (11-2 g/dl) at admission or during the first 48 hours after acute myocardial infarction were regarded as an indication for blood transfusion.
Bleeding was defined as the occurrence of haematoma, haemoptysis, haematemesis, melaena, haematuria, or an intracranial event within 48 hours of admission. Swelling was regarded as an essential feature of the diagnosis of haematoma at the puncture site. To estimate the change in haematocrit during routine heart catheterisation, we studied 43 other patients, aged < 70 years, undergoing elective coronary angiography and left ventricular cineangiography because of chest pain. The haematocrit Bleeding and intracoronary streptokinase catheter sheath was removed immediately after the patients had received 50 mg of protamine sulphate intravenously.
STATISTICAL ANALYSIS
The results were analysed by Student's t test for either unpaired or paired data, or by the x2 test for frequency distribution analysis.
Results

CHARACTERISTICS OF PATIENTS BEFORE RANDOMISATION
Apart from the more frequent use of anti-platelet drugs in the control group there were no signficant differences between the two groups before randomisation (Table 1 Table 3 shows the characteristics, the dose of streptokinase, and the fall in haematocrit in these patients in relation to bleeding complications. There were no differences in the characteristics before randomisation among the three groups. As expected, in the streptokinase group there was a larger fall in haematocrit in the patients with manifest bleeding than in those without. The fall in haematocrit in the latter group, however, is still significantly higher than in the controls, indicating that there may have been occult bleeding without manifest bleeding in the streptokinase treated patients. The dose of streptokinase was similar in patients with manifest bleeding complications and in those without. (0 05 (0 03)) in the patients without systemic fibrinolysis was greater than the fall in those with fibrinolysis (0-01 (0-03), p <005). There was manifest bleeding in four patients (21%) with systemic fibrinolysis and in none of the patients without systemic fibrinolysis.
DOSE OF INTRACORONARY STREPTOKINASE AND FALL IN HAEMATOCRIT
There was no correlation between the dose of intracoronary streptokinase given to the 97 patients shown in Table 3 and the fall in haematocrit (Figure) .
HAEMATOCRIT BEFORE AND AFTER ELECTIVE CATHETERISATION
There was no change in haematocrit in patients undergoing elective heart catheterisation (0-45 (0 02) before and 0-45 (0-04) 24 hours after catheterisation).
Discussion
Although controlled trials have not confirmed the efficacy of intravenous streptokinase treatment in acute myocardial infarction,112 they have shown that a dose of 2 5 million units in 24 hours may safely be given. There were reports of non-fatal bleeding complications in 0-25% of patients but they did not require transfusion. 1 -13 The effective intracoronary dose of streptokinase is quite low but arterial puncture and instrumentation themselves increase the risk of bleeding. The reported frequency of haemorrhagic complications associated with intracoronary streptokinase varies from 0% to 23%. 3414 15 Isolated reports of bleeding after intracoronary streptokinase"6 may merely reflect normal complications of myocardial infarction. Haemorrhagic infarction1718 with or without ventricular rupture can occur without fibrinolytic treatment.
We found bleeding in 16% of patients treated with intracoronary streptokinase. Bleeding occurred exclusively at the femoral puncture site and substantial transfusion support was necessary. Bleeding resulted in a large drop in haematocrit.
The haematocrit usually falls to 0-02 in the first few days after acute myocardial infarction. 19 There is a definite risk of non-fatal major arterial bleeding associated with intracoronary streptokinase treatment. This is attributable to the combined use of streptokinase with a catheterisation procedure. Bleeding was three times more common in patients over the age of 60 than in younger patients and tended to be more common in females. The appearance of a groin haematoma after intracoronary streptokinase treatment indicates important bleeding and transfusion support was required by about 70% of patients with this complication. The use of more specific fibrinolytic agents such as tissue plasminogen activator,23 might avoid these complications. 
